- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 20, Issue 16, 2019
Current Drug Targets - Volume 20, Issue 16, 2019
Volume 20, Issue 16, 2019
-
-
Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia
Authors: Eman M. Hamed, Mohamed H. Meabed, Usama Farghaly Aly and Raghda R.S. HusseinBeta-thalassemia is a genetic disorder characterized by the impaired synthesis of the betaglobin chain of adult hemoglobin. The disorder has a complex pathophysiology that affects multiple organ systems. The main complications of beta thalassemia are ineffective erythropoiesis, chronic hemolytic anemia and hemosiderosis-induced organ dysfunction. Regular blood transfusions are the main therapy for beta thalassemia Read More
-
-
-
Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Implementation of novel and biocompatible polymers in drug design is an emerging and rapidly growing area of research. Even though we have a large number of polymer materials for various applications, the biocompatibility of these materials remains as a herculean task for researchers. Aptamers provide a vital and efficient solution to this problem. They are usually small (ranging from 20 to 60 nucleotides, single-strande Read More
-
-
-
Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
Authors: Bing-Yi Zhang, Dan-Ping Chai, Yi-Hang Wu, Li-Peng Qiu, Yong-Yong Zhang, Zi-Hong Ye and Xiao-Ping YuBackground: Hepatitis B is a very harmful and epidemic disease caused by hepatitis B virus (HBV). Although an effective anti-HBV vaccine is available, chronic infection poses still a huge health burden in the whole world. The present anti-HBV drugs including nucleoside analogues and interferonalpha have their limitations without exception. There is no effective drug and therapeutic method that can really and truly cur Read More
-
-
-
Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia
Schizophrenia is a debilitating mental disorder with relatively high prevalence (~1%), during which positive manifestations (such as psychotic states) and negative symptoms (e.g., a withdrawal from social life) occur. Moreover, some researchers consider cognitive impairment as a distinct domain of schizophrenia symptoms. The imbalance in dopamine activity, namely an excessive release of this neurotransmitter in the striatum a Read More
-
-
-
Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis
Authors: Olorunfemi A. Oshagbemi, Jephthah O. Odiba, Abraham Daniel and Ismaeel YunusaIntroduction: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 recommends the use of absolute blood eosinophil count as a guide for the escalation and de-escalation of inhaled corticosteroids (ICS) in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). We evaluated the risk of moderate or severe exacerbations among patients escalating and de-escalating IC Read More
-
-
-
Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation
Authors: Ammu P. Kumar, Sungmun Lee and Suryani LukmanAmylin is a neuroendocrine peptide hormone secreted by pancreatic β-cells; however, amylin is toxic to β-cells when it is aggregated in type 2 diabetes mellitus (T2DM). It is important to understand amylin’s structures and aggregation mechanism for the discovery and design of effective drugs to inhibit amylin aggregation. In this review, we investigated experimental and computational studies on amylin structures and inh Read More
-
-
-
Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis
Authors: Tetsumei Urano, Yuko Suzuki, Takayuki Iwaki, Hideto Sano, Naoki Honkura and Francis J. CastellinoThe fibrinolytic system consists of a balance between rates of plasminogen activation and fibrin degradation, both of which are finely regulated by spatio-temporal mechanisms. Three distinct inhibitors of the fibrinolytic system that differently regulate these two steps are plasminogen activator inhibitor type-1 (PAI-1), α2-antiplasmin, and thrombin activatable fibrinolysis inhibitor (TAFI). In this review, we focus on the mechanisms Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
